SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Cederholm Tommy E.)
 

Sökning: WFRF:(Cederholm Tommy E.) > Transfer of omega-3...

Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease : the OmegAD study

Freund-Levi, Yvonne, 1956- (författare)
Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
Vedin, I (författare)
Karolinska Institutet
Cederholm, Tommy (författare)
Karolinska Institutet,Uppsala universitet,Klinisk nutrition och metabolism
visa fler...
Basun, Hans (författare)
Uppsala universitet,Geriatrik
Faxén Irving, G (författare)
Karolinska Institutet
Eriksdotter, M (författare)
Karolinska Institutet
Hjorth, E (författare)
Karolinska Institutet
Schultzberg, M (författare)
Karolinska Institutet
Vessby, Bengt (författare)
Uppsala universitet,Klinisk nutrition och metabolism
Wahlund, L-O (författare)
Karolinska Institutet,Uppsala universitet,Geriatrik
Salem, N, Jr (författare)
National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville MD, United States
Palmblad, J (författare)
Karolinska Institutet
visa färre...
 (creator_code:org_t)
2014-01-11
2014
Engelska.
Ingår i: Journal of Internal Medicine. - : Blackwell Publishing. - 0954-6820 .- 1365-2796. ; 275:4, s. 428-436
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • OBJECTIVE: Little is known about the transfer of essential fatty acids (FAs) across the human blood-brain barrier (BBB) in adulthood. In this study, we investigated whether oral supplementation with omega-3 (n-3) FAs would change the FA profile of the cerebrospinal fluid (CSF).METHODS: A total of 33 patients (18 receiving the n-3 FA supplement and 15 receiving placebo) were included in the study. These patients were participants in the double-blind, placebo-controlled randomized OmegAD study in which 204 patients with mild Alzheimer's disease (AD) received 2.3 g n-3 FA [high in docosahexaenoic acid (DHA)] or placebo daily for 6 months. CSF FA levels were related to changes in plasma FA and to CSF biomarkers of AD and inflammation.RESULTS: At 6 months, the n-3 FA supplement group displayed significant increases in CSF (and plasma) eicosapentaenoic acid (EPA), DHA and total n-3 FA levels (P < 0.01), whereas no changes were observed in the placebo group. Changes in CSF and plasma levels of EPA and n-3 docosapentaenoic acid were strongly correlated, in contrast to those of DHA. Changes in DHA levels in CSF were inversely correlated with CSF levels of total and phosphorylated tau, and directly correlated with soluble interleukin-1 receptor type II. Thus, the more DHA increased in CSF, the greater the change in CSF AD/inflammatory biomarkers.CONCLUSIONS: Oral supplementation with n-3 FAs conferred changes in the n-3 FA profile in CSF, suggesting transfer of these FAs across the BBB in adults.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Nyckelord

Alzheimer's disease
cerebrospinal fluid
docosahexaenoic acid
eicosapentaenoic acid
omega-3 fatty acids

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy